|
1
|
Filmus J: Glypicans in growth control and
cancer. Glycobiology. 11:19R–23R. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Iglesias BV, Centeno G, Pascuccelli H,
Ward F, Peters MG, Filmus J, Puricelli L and de Kier Joffé EB:
Expression pattern of glypican-3 (GPC3) during human embryonic and
fetal development. Histol Histopathol. 23:1333–1340.
2008.PubMed/NCBI
|
|
3
|
DeBaun MR, Ess J and Saunders S: Simpson
Golabi Behmel syndrome: Progress toward understanding the molecular
basis for overgrowth, malformation, and cancer predisposition. Mol
Genet Metab. 72:279–286. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lapunzina P: Risk of tumorigenesis in
overgrowth syndromes: A comprehensive review. Am J Med Genet C
Semin Med Genet. 137C:53–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schirwani S, Novelli A, Digilio MC, Bourn
D, Wilson V, Roberts C, Dallapiccola B and Hobson E: Duplications
of GPC3 and GPC4 genes in symptomatic female carriers of
simpson-golabi-behmel syndrome type 1. Eur J Med Genet pii.
S1769-7212:30203–30209. 2018.
|
|
6
|
Nakatsura T, Yoshitake Y, Senju S, Monji
M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H,
et al: Glypican-3, overexpressed specifically in human
hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys
Res Commun. 306:16–25. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Levy M, Trivedi A, Zhang J, Miles L,
Mattis AN, Kim GE, Lassman C, Anders RA, Misdraji J, Yerian LM, et
al: Expression of glypican-3 in undifferentiated embryonal sarcoma
and mesenchymal hamartoma of the liver. Hum Pathol. 43:695–701.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xing XL, Qin H, Yan SQ, Zhou LS, Chen P
and Zhao D: Expression of glypican-3 is highly associated with
pediatric hepatoblastoma: A systemic analysis. Asian Pac J Cancer
Prev. 16:1029–1031. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kinoshita Y, Tanaka S, Souzaki R, Miyoshi
K, Kohashi K, Oda Y, Nakatsura T and Taguchi T: Glypican 3
expression in pediatric malignant solid tumors. Eur J Pediatr Surg.
25:138–144. 2015.PubMed/NCBI
|
|
10
|
Kohashi K, Nakatsura T, Kinoshita Y,
Yamamoto H, Yamada Y, Tajiri T, Taguchi T, Iwamoto Y and Oda Y:
Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein
expression. Hum Pathol. 44:526–533. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saikali Z and Sinnett D: Expression of
glypican 3 (GPC3) in embryonal tumors. Int J Cancer. 89:418–422.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ota S, Hishinuma M, Yamauchi N, Goto A,
Morikawa T, Fujimura T, Kitamura T, Kodama T, Aburatani H and
Fukayama M: Oncofetal protein glypican-3 in testicular germ-cell
tumor. Virchows Arch. 449:308–314. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aviel-Ronen S, Lau SK, Pintilie M, Lau D,
Liu N, Tsao MS and Jothy S: Glypican-3 is overexpressed in lung
squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol.
21:817–825. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thway K, Selfe J, Missiaglia E, Fisher C
and Shipley J: Glypican-3 is expressed in rhabdomyosarcomas but not
adult spindle cell and pleomorphic sarcomas. J Clin Pathol.
64:587–591. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakatsura T, Kageshita T, Ito S, Wakamatsu
K, Monji M, Ikuta Y, Senju S, Ono T and Nishimura Y: Identification
of glypican-3 as a novel tumor marker for melanoma. Clin Cancer
Res. 10:6612–6621. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baer C, Nees M, Breit S, Wakamatsu K,
Monji M, Ikuta Y, Senju S, Ono T and Nishimura Y: Profiling and
functional annotation of mRNA gene expression in pediatric
rhabdomyosarcoma and Ewing's sarcoma. Int J Cancer. 110:687–694.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sawada Y, Yoshikawa T, Nobuoka D,
Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K,
Konishi M, et al: Phase I trial of a glypican-3-derived peptide
vaccine for advanced hepatocellular carcinoma: Immunologic evidence
and potential for improving overall survival. Clin Cancer Res.
18:3686–3696. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shirakawa H, Suzuki H, Shimomura M, Kojima
M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N,
Kinoshita T and Nakatsura T: Glypican-3 expression is correlated
with poor prognosis in hepatocellular carcinoma. Cancer Sci.
100:1403–1407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J, Zhang M, Ma H, Song X, He L, Ye X
and Li X: Overexpression of glypican-3 is a predictor of poor
prognosis in hepatocellular carcinoma: An updated meta-analysis.
Medicine (Baltimore). 97:e1111302018.
|
|
20
|
Midorikawa Y, Ishikawa S, Iwanari H,
Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M and
Aburatani H: Glypican-3, overexpressed in hepatocellular carcinoma,
modulates FGF2 and BMP-7 signaling. Int J Cancer. 103:455–465.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chan ES, Pawel BR, Corao DA, Venneti S,
Russo P, Santi M and Sullivan LM: Immunohistochemical expression of
glypican-3 in pediatric tumors: An analysis of 414 cases. Pediatr
Dev Pathol. 16:272–277. 2013. View Article : Google Scholar : PubMed/NCBI
|
